[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,713,469
  • Shares Outstanding, K 186,746
  • Annual Sales, $ 0 K
  • Annual Income, $ -446,210 K
  • EBIT $ -537 M
  • EBITDA $ -537 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.70

Options Overview Details

View History
  • Implied Volatility 86.10% (+6.95%)
  • Historical Volatility 42.69%
  • IV Percentile 7%
  • IV Rank 7.59%
  • IV High 253.75% on 10/21/25
  • IV Low 72.33% on 08/18/25
  • Expected Move (DTE 16) 0.85 (3.27%)
  • Put/Call Vol Ratio 1.19
  • Today's Volume 309
  • Volume Avg (30-Day) 390
  • Put/Call OI Ratio 4.41
  • Today's Open Interest 9,048
  • Open Int (30-Day) 6,515
  • Expected Range 25.12 to 26.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.80
  • Number of Estimates 9
  • High Estimate $-0.68
  • Low Estimate $-0.95
  • Prior Year $-0.76
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.28 +22.04%
on 07/16/26
26.26 -1.10%
on 07/28/26
+2.90 (+12.57%)
since 07/02/26
3-Month
15.87 +63.64%
on 05/19/26
26.26 -1.10%
on 07/28/26
+8.26 (+46.64%)
since 05/04/26
52-Week
9.89 +162.59%
on 08/06/25
26.26 -1.10%
on 07/28/26
+15.72 (+153.37%)
since 08/04/25

Most Recent Stories

More News
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

-  Company’s third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - WALTHAM, Mass., July 28,...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Reports Earnings Days After Pricing a Three Hundred Million Dollar Raise

Barchart Research What to Expect from DYN Earnings DYN Generated July 24, 2026 Current Price $24.44 EPS Estimate $$-0.74 Consensus Rating Strong Buy Average Move 5.96% Dyne Therapeutics Reports Earnings...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Appoints Barry Greene to Board of Directors

WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 25.97 (+2.89%)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 25.97 (+2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 27.18
2nd Resistance Point 26.63
1st Resistance Point 26.30
Last Price 25.97
1st Support Level 25.42
2nd Support Level 24.87
3rd Support Level 24.54

See More

52-Week High 26.26
Last Price 25.97
Fibonacci 61.8% 20.01
Fibonacci 50% 18.08
Fibonacci 38.2% 16.14
52-Week Low 9.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.